Maximum Dose of Empagliflozin and Gliclazide
The maximum recommended daily dose of empagliflozin is 25 mg once daily, and for gliclazide modified release, the maximum dose is 120 mg once daily.
Empagliflozin Maximum Dosing
The FDA-approved maximum clinical dose of empagliflozin is 25 mg once daily 1. This dosing is supported by:
- Clinical trial evidence demonstrating that doses of 10 mg and 25 mg once daily are effective and well-tolerated, with dose-proportional increases in drug exposure 2
- Safety data showing that even doses up to 100 mg daily were studied, but the 25 mg dose provides optimal efficacy without additional benefit at higher doses 2
- Current guidelines from the American Diabetes Association (2025) recognize empagliflozin as an SGLT2 inhibitor with proven cardiovascular and renal benefits at standard dosing 3
Key Dosing Considerations for Empagliflozin:
- Renal function: The glucose-lowering effect is minimal at eGFR <45 mL/min/1.73 m², but the medication should be continued for cardiovascular and kidney benefits until dialysis or transplantation 3
- No dose adjustment needed for most patients with renal impairment when using for cardiorenal protection 3
- Single daily administration is sufficient due to the drug's pharmacokinetic profile 2
Gliclazide Maximum Dosing
For gliclazide modified release formulation, the maximum dose is 120 mg once daily 4. The immediate-release formulation can be dosed up to 320 mg/day in divided doses 4.
Key Dosing Considerations for Gliclazide:
- Modified release formulation (30-120 mg once daily) provides 24-hour glycemic control with once-daily dosing 4
- Immediate release formulation requires divided doses when exceeding 80 mg daily 4
- Hypoglycemia risk: When combining with empagliflozin or other glucose-lowering agents, insulin secretagogues like gliclazide increase hypoglycemia risk and may require dose reduction 1
Clinical Implications When Using Both Medications
Important caveat: When empagliflozin is added to gliclazide therapy, the risk of hypoglycemia increases 1. Consider:
- Reducing gliclazide dose when initiating empagliflozin, particularly if baseline glucose control is near target
- Close monitoring for hypoglycemia, especially in the first few weeks of combination therapy
- Patient education on recognizing and managing hypoglycemia
The combination of these agents at maximum doses (empagliflozin 25 mg + gliclazide 120 mg) should be reserved for patients with significantly elevated HbA1c who require aggressive glucose lowering, with careful attention to hypoglycemia risk.